Related Experiment Videos
Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol
J C Perry1, A L Fenrich, J E Hulse
1Children's Hospital San Diego, California, USA.
Insights
Intravenous amiodarone effectively treats critical, drug-resistant tachyarrhythmias in pediatric patients when standard therapies fail. This study demonstrates its safety and lifesaving potential, particularly for postoperative junctional ectopic tachycardia.
Area of Science:
- Pediatric Cardiology
- Clinical Pharmacology
- Critical Care Medicine
Background:
- Limited data exists on intravenous amiodarone use in pediatric populations.
- Adult studies on intravenous amiodarone began in the early 1980s.
- A larger pediatric cohort is needed for safe usage guidelines.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous amiodarone for critical, drug-resistant arrhythmias in young patients.
- To establish guidelines for amiodarone's use in pediatric populations.
- To assess amiodarone's role in managing refractory tachyarrhythmias.
Main Methods:
- Multi-center study involving eight institutions with a standardized protocol.
- Compassionate use approvals obtained for additional centers.
- Standardized protocol for intravenous amiodarone administration and monitoring.
Main Results:
- Forty pediatric patients with refractory tachyarrhythmias were enrolled.
- Intravenous amiodarone showed high success rates in postoperative tachyarrhythmias (84%) and junctional ectopic tachycardia (93%).
- Adverse events were mild, including transient hypotension and bradycardia; no proarrhythmic effects or amiodarone-related deaths were observed.
Conclusions:
- Intravenous amiodarone is a safe and effective treatment for critical tachyarrhythmias in pediatric patients.
- Amiodarone can be lifesaving, especially for postoperative junctional ectopic tachycardia unresponsive to other treatments.
- The drug offers a vital therapeutic option when conventional therapies are insufficient.
Objective:
The purpose of this study was to analyze the efficacy and safety of intravenous amiodarone in young patients with critical, drug-resistant arrhythmias.
Background:
Intravenous amiodarone has been investigated in adults since the early 1980s. Experience with the drug in young patients is limited. A larger pediatric study group was necessary to provide responsible guidelines for the drug's use before its market release.
Methods:
Eight centers obtained institutional approval of a standardized protocol. Other centers were approved on a compassionate use basis after contacting the primary investigator (J.C.P).
Results:
Forty patients were enrolled. Standard management in all failed. Many patients had early postoperative tachyarrhythmias (25 of 40), with early successful treatment in 21 (84%) of 25. Twelve patients had ventricular tachyarrhythmias: seven had successful therapy, and six died, none related to the drug. Eleven patients had atrial tachyarrhythmias: 10 of 11 had immediate success, but 3 later died. Fourteen patients had junctional ectopic tachycardia, which was treated with success (sinus rhythm or slowing, allowing pacing) in 13 of 14, with no deaths. Three other patients had supraventricular tachycardias, with success in two and no deaths. The average loading dose was 6.3 mg/kg body weight, and 50% of patients required a continuous infusion. Four patients had mild hypotension during the amiodarone bolus. One postoperative patient experienced bradycardia requiring temporary pacing. There were no proarrhythmic effects. Deaths (9 [23%] of 40) were not attributed to amiodarone.
Conclusions:
Intravenous amiodarone is safe and effective in most young patients with critical tachyarrhythmia. Intravenous amiodarone can be lifesaving, particularly for postoperative junctional ectopic tachycardia, when standard therapy is ineffective.